XML 28 R17.htm IDEA: XBRL DOCUMENT v3.21.2

ANNUAL RESTRICTED STOCK GRANTS TO DIRECTORS	9 Months Ended
	Sep. 30, 2021
Equity [Abstract]
ANNUAL RESTRICTED STOCK GRANTS TO DIRECTORS	11. ANNUAL RESTRICTED STOCK GRANTS TO DIRECTORS On September 30, 2021 the company granted each of our two non-employee directors annual restricted stock grants of 2,900 shares of our common stock and our lead independent director an annual restricted stock grant of 4,000 shares of common stock, which vest quarterly in four (4) equal installments beginning on December 31, 2021. On the grant date, these shares had a per share fair value of $27.37 based on the closing trading price of our common stock, or $268,234. There was no expense recognized in the quarter ended September 30, 2021. On April 1, 2021, the Board approved two restricted stock grants to Mr. Wheatley under the 2011 Stock Incentive Plan. The total number of shares granted was determined based on an award of $112,500, divided by the per share closing trading price on April 1, 2021. On the grant date, the shares had a per share fair value of $40.10 and 2,806 shares were granted, half of which will vest quarterly over three equal installments and half of which will vest quarterly over 11 equal installments. During the six months ended September 30, 2021, 1,192 of these shares vested generating an expense of $47,728. At September 30, 2021, 1,614 shares are unvested representing $64,772 of unrecognized restricted stock grant expense which will be recognized through the quarter ending December 31, 2023. On April 16, 2021, the Board appointed Nancy Floyd to the Company’s board of directors. Concurrent with her appointment, the Company, upon recommendation of the Compensation Committee, granted Ms. Floyd 5,592 shares of restricted stock which had a per share fair value of $33.34 on the date of grant and will vest quarterly through September 30, 2021. During the nine months ended September 30, 2021, all 5,592 shares vested generating an expense of $186,426. At September 30, 2021, all of these shares were vested, and no unrecognized restricted stock grant expense remained. On April 16, 2021, the Board appointed Mr. Posawatz as the Lead Independent Director. With this appointment, the Company, upon recommendation of the Compensation Committee, granted Mr. Posawatz 2,246 shares of restricted stock for this role which had a per share fair value of $33.34 on the date of grant and will vest quarterly through September 30, 2021. During the nine months ended September 30, 2021, all 2,246 shares vested generating an expense of $74,876. At September 30, 2021, all of these shares were vested, and no unrecognized restricted stock grant expense remained. On October 20, 2020, the Company granted each of our two non-employee directors annual restricted stock grants of 12,200 shares of our common stock and our then lead independent director an annual restricted stock grant of 17,100 shares of common stock, which vest quarterly in four (4) equal installments. On the grant date, these shares had a per share fair value of $14.95 based on the closing trading price of our common stock, or $620,425. During the three months ended March 31, 2021, upon the death of our lead independent director, 12,825 unvested shares of restricted stock were forfeited and returned to the Company. During the nine months ended September 30, 2021, 18,300 shares of restricted stock relating to the other two directors vested, generating an expense of $273,584. At September 30, 2021, all of these shares were vested, and no unrecognized restricted stock grant expense remained. On June 17, 2020, the Board approved two restricted stock grants to Mr. Wheatley under the 2011 Stock Incentive Plan. The total number of shares granted was determined based on an award of $150,000 divided by the per share quoted trading price on June 17, 2020. On the grant date, the shares had a per share fair value of $7.35 and 20,408 shares were granted, half of which vest quarterly over four equal installments and half vest quarterly over 12 equal installments. During the nine months ended September 30, 2021, 5,101 shares from this grant vested and 3,141 shares from an October 1, 2019 grant vested generating a total expense of $56,250. At September 30, 2021, 7,196 shares for these 2 grants are unvested representing $50,000 of unrecognized restricted stock grant expense which will be recognized through the quarter ending March 31, 2023.

X

- References

No definition available.

+ Details

Name:	us-gaap_EquityAbstract
Namespace Prefix:	us-gaap_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

X

- Definition

The entire disclosure for shareholders' equity and share-based payment arrangement. Includes, but is not limited to, disclosure of policy and terms of share-based payment arrangement, deferred compensation arrangement, and employee stock purchase plan (ESPP).

+ References

Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-URI http://asc.fasb.org/topic&trid=2208762

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-URI http://asc.fasb.org/topic&trid=2228938

+ Details

Name:	us-gaap_ShareholdersEquityAndShareBasedPaymentsTextBlock
Namespace Prefix:	us-gaap_
Data Type:	dtr-types:textBlockItemType
Balance Type:	na
Period Type:	duration